AstraZeneca’s RSV drug MEDI8897 gets FDA’s breakthrough therapy designation

Image: AstraZeneca’s MEDI8897 gets FDA’s breakthrough therapy designation and EMA’s PRIME eligibility. Photo: courtesy of Astrazeneca.